Trial · NCT02654639
Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
NCT02654639, Phase 2, Terminated, Georgetown University; results first posted 2018-08-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer. Trials, record NCT02654639. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02654639
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
- NCT number
- NCT02654639
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- Georgetown University
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- TAS-102, Bevacizumab
- First posted
- 2016-01-13
- Last updated
- 2018-08-07
- Results first posted
- 2018-08-07
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Length of Progression-Free Survival | From the first occurrence of progression or death, whichever occurred first, assessed up to 2 years. | Disease progression will be assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Length of Progression-Free Survival | From the first occurrence of progression or death, whichever occurred first, assessed up to 2 years. | The study was terminated early due to recruitment difficulties. 4 subjects were enrolled but no outcomes data was collected and no analysis was performed. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | TAS-102 and Bevacizumab | 4 | |
| Overall Study | COMPLETED | TAS-102 and Bevacizumab | 4 | |
| Overall Study | NOT COMPLETED | TAS-102 and Bevacizumab | 0 |
Source ClinicalTrials.gov
Adverse events21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Hepatobiliary disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Diarrhea | Gastrointestinal disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Neutrophil count decreased | Immune system disorders | TAS-102 and Bevacizumab | 2 | 4 | 4 |
| other | Pain | General disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Palmar-plantar erythrodysesthesia syndrome | Skin and subcutaneous tissue disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Vomiting | Gastrointestinal disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Fatigue | General disorders | TAS-102 and Bevacizumab | 2 | 4 | 2 |
| other | Nervous system disorders - Other | Nervous system disorders | TAS-102 and Bevacizumab | 1 | 4 | 2 |
| other | Hepatic failure | Hepatobiliary disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | TAS-102 and Bevacizumab | 0 | 4 |
| Total, other adverse events | TAS-102 and Bevacizumab | 4 | 4 |
| Total, serious adverse events | TAS-102 and Bevacizumab | 1 | 4 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28712102 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02654639
GET https://conductscience.org/api/trials/v1/NCT02654639/events?page=2